Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine
Crossref DOI link: https://doi.org/10.1038/s41571-019-0264-7
Published Online: 2019-08-30
Published Print: 2019-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kimmelman, Jonathan http://orcid.org/0000-0003-1614-6779
Text and Data Mining valid from 2019-08-30
Version of Record valid from 2019-08-30
Article History
First Online: 30 August 2019
Competing interests
: The author serves in a remunerative capacity on a DSMB for a (non-cancer) phase I trial of Ultragenyx.